Iron dysregulation in beta-thalassemia

MacKenzie, 2008, Intracellular iron transport and storage: from molecular mechanisms to health implications, Antioxid Redox Sign, 10, 997, 10.1089/ars.2007.1893 Kaplan, 2011, The molecular basis of iron overload disorders and iron-linked anemias, Int J Hematol, 93, 14, 10.1007/s12185-010-0760-0 Fuqua, 2012, Intestinal iron absorption, J Trace Elem Med Biol, 26, 115, 10.1016/j.jtemb.2012.03.015 Hershko, 1978, Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity, Br J Haematol, 40, 255, 10.1111/j.1365-2141.1978.tb03662.x Ganz, 2012, Hepcidin and iron homeostasis, Biochim Biophys Acta, 1823, 1434, 10.1016/j.bbamcr.2012.01.014 Conrad, 2000, Separate pathways for cellular uptake of ferric and ferrous iron, Am J Physiol Gastrointest Liver Physiol, 279, 767, 10.1152/ajpgi.2000.279.4.G767 Fleming, 1997, Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene, Nat Genet, 16, 383, 10.1038/ng0897-383 San Martin, 2008, Caco-2 intestinal epithelial cells absorb soybean ferritin by mu2 (AP2)-dependent endocytosis, J Nutr, 138, 659 Abboud, 2000, A novel mammalian iron-regulated protein involved in intracellular iron metabolism, J Biol Chem, 275, 19906, 10.1074/jbc.M000713200 Donovan, 2000, Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter, Nature, 403, 776, 10.1038/35001596 McKie, 2000, A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation, Mol Cell, 5, 299, 10.1016/S1097-2765(00)80425-6 Ohgami, 2005, Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells, Nat Genet, 37, 1264, 10.1038/ng1658 Ohgami, 2006, The Steap proteins are metalloreductases, Blood, 108, 1388, 10.1182/blood-2006-02-003681 Knutson, 2003, Iron loading and erythrophagocytosis increase ferroportin 1 (FPN1) expression in J774 macrophages, Blood, 102, 4191, 10.1182/blood-2003-04-1250 Liu, 2002, Role of the ferroportin iron-responsive element in iron and nitric oxide dependent gene regulation, Blood Cells Mol Dis, 29, 315, 10.1006/bcmd.2002.0572 Lymboussaki, 2003, The role of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene expression, J Hepatol, 39, 710, 10.1016/S0168-8278(03)00408-2 Cianetti, 2005, Expression of alternative transcripts of ferroportin-1 during human erythroid differentiation, Haematologica, 90, 1595 Zhang, 2009, A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression, Cell Metab, 9, 461, 10.1016/j.cmet.2009.03.006 Jordan, 2009, Hepcidin revisited, disulfide connectivity, dynamics, and structure, J Biol Chem, 284, 24155, 10.1074/jbc.M109.017764 Park, 2001, Hepcidin, a urinary antimicrobial peptide synthesized in the liver, J Biol Chem, 276, 7806, 10.1074/jbc.M008922200 Nemeth, 2009, The role of hepcidin in iron metabolism, Acta Haematol, 122, 78, 10.1159/000243791 Laftah, 2004, Effect of hepcidin on intestinal iron absorption in mice, Blood, 103, 3940, 10.1182/blood-2003-03-0953 Silvestri, 2008, The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin, Cell Metab, 8, 502, 10.1016/j.cmet.2008.09.012 Schmidt, 2013, An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia, Blood, 121, 1200, 10.1182/blood-2012-09-453977 Silvestri, 2013, Inhibiting the hepcidin inhibitor for treatment of iron overload, Blood, 121, 1068, 10.1182/blood-2012-12-472597 Nemeth, 2004, IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin, J Clin Invest, 113, 1271, 10.1172/JCI200420945 Sakamori, 2010, STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo, J Gastroenterol, 45, 244, 10.1007/s00535-009-0159-y Tanno, 2007, High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin, Nat Med, 13, 1096, 10.1038/nm1629 Tanno, 2009, Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells, Blood, 114, 181, 10.1182/blood-2008-12-195503 Kautz, 2014, Identification of erythroferrone as an erythroid regulator of iron metabolism, Nat Genet, 46, 678, 10.1038/ng.2996 Higgs, 2012, Thalassaemia, Lancet, 379, 373, 10.1016/S0140-6736(11)60283-3 Marks, 1971, Molecular pathology of thalassemia syndromes, Fed Proc, 30, 977 Villegas, 2001, The thalassemia syndromes: molecular characterization in the Spanish population, Hemoglobin, 25, 273, 10.1081/HEM-100105220 Rund, 2005, Beta-thalassemia, N Engl J Med, 353, 1135, 10.1056/NEJMra050436 Olivieri, 1999, The beta-thalassemias, N Engl J Med, 341, 99, 10.1056/NEJM199907083410207 Ho, 2000, Gene regulation and deregulation: a beta globin perspective, Blood Rev, 14, 78, 10.1054/blre.2000.0128 Gibbons, 2001, Thalassaemia syndromes, 287 Nienhuis, 2012, Pathophysiology and clinical manifestations of the beta-thalassemias, Cold Spring Harb Perspect Med, 2, 10.1101/cshperspect.a011726 Fucharoen, 2001, 1147 Fucharoen, 1987, Variable severity of Southeast Asian beta 0-thalassemia/Hb E disease, Birth Defects Orig Artic Ser, 23, 241 Fairbanks, 1980, Homozygous hemoglobin E mimics beta-thalassemia minor without anemia or hemolysis: hematologic, functional, and biosynthetic studies of first North American cases, Am J Hematol, 8, 109, 10.1002/ajh.2830080112 Fucharoen, 2001, Disorders of hemoglobin: genetics, pathophysiology, and clinical management, 1139 Sripichai, 2005, Genetic analysis of candidate modifier polymorphisms in Hb E-beta 0-thalassemia patients, Ann N Y Acad Sci, 1054, 433, 10.1196/annals.1345.066 Winichagoon, 1993, Severity differences in beta-thalassaemia/haemoglobin E syndromes: implication of genetic factors, Br J Haematol, 83, 633, 10.1111/j.1365-2141.1993.tb04702.x Mathias, 2000, Ineffective erythropoiesis in beta-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage, Exp Hematol, 28, 1343, 10.1016/S0301-472X(00)00555-5 Schrier, 2002, Pathophysiology of thalassemia, Curr Opin Hematol, 9, 123, 10.1097/00062752-200203000-00007 Rachmilewitz, 1969, Role of haemichromes in the formation of inclusion bodies in haemoglobin H disease, Nature, 222, 248, 10.1038/222248a0 Rachmilewitz, 1971, Studies on the stability of oxyhemoglobin A and its constituent chains and their derivatives, J Biol Chem, 246, 3356, 10.1016/S0021-9258(18)62233-1 Arlet, 2016, Novel players in beta-thalassemia dyserythropoiesis and new therapeutic strategies, Curr Opin Hematol, 23, 181, 10.1097/MOH.0000000000000231 Pootrakul, 2000, A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia, Blood, 96, 2606, 10.1182/blood.V96.7.2606.h8002606_2606_2612 Centis, 2000, The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major, Blood, 96, 3624, 10.1182/blood.V96.10.3624 Chen, 1992, Peripheral blood hematopoietic progenitor cells in beta-thalassemia major, Int J Cell Cloning, 10, 338, 10.1002/stem.5530100605 Kittikalayawong, 2005, Enhanced maturation and proliferation of beta-thalassemia/Hb E erythroid precursor cells in culture, Southeast Asian J Trop Med Public Health, 36, 1298 Mai, 2007, Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia, Mol Pharmacol, 72, 1111, 10.1124/mol.107.036772 Weatherall, 2001, Thalassaemia syndromes, 192 Nancy, 2001, Disorders of hemoglobin: genetics, pathophysiology, and clinical management, 277 Polliack, 1974, Ultrastructure of the inclusion bodies and nuclear abnormalities in beta-thalassemic erythroblasts, Ann N Y Acad Sci, 232, 261, 10.1111/j.1749-6632.1974.tb20591.x Wickramasinghe, 1975, Observations on the ultrastructure of erythropoietic cells and reticulum cells in the bone marrow of patients with homozygous beta-thalassaemia, Br J Haematol, 30, 395, 10.1111/j.1365-2141.1975.tb01853.x Wickramasinghe, 1981, Ineffective erythropoiesis in haemoglobin E beta-thalassaemia: an electron microscope study, Br J Haematol, 48, 451, 10.1111/j.1365-2141.1981.tb02737.x Modell, 1974, Haemoglobinopathies. The pathophysiology of beta-thalassaemia major, J Clin Pathol Suppl (R Coll Pathol), 8, 12, 10.1136/jcp.s3-8.1.12 Yuan, 1993, Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia), Blood, 82, 374, 10.1182/blood.V82.2.374.374 Borenstain-Ben Yashar, 1993, Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes, Am J Hematol, 44, 63, 10.1002/ajh.2830440114 Kihm, 2002, An abundant erythroid protein that stabilizes free alpha-haemoglobin, Nature, 417, 758, 10.1038/nature00803 Arlet, 2014, HSP70 sequestration by free alpha-globin promotes ineffective erythropoiesis in beta-thalassaemia, Nature, 514, 242, 10.1038/nature13614 Chaisiripoomkere, 1999, Serum erythropoietin levels in thalassemia major and intermedia, Southeast Asian J Trop Med Public Health, 30, 786 Nisli, 1997, Serum erythropoietin levels in patients with beta thalassemia major and intermedia, Pediatr Hematol Oncol, 14, 161, 10.3109/08880019709030902 Paritpokee, 2002, Serum erythropoietin levels in pediatric patients with beta-thalassemia/hemoglobin E, Clin Lab, 48, 631 Ginzburg, 2011, beta-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism, Blood, 118, 4321, 10.1182/blood-2011-03-283614 Borgna-Pignatti, 2005, Survival and complications in thalassemia, Ann N Y Acad Sci, 1054, 40, 10.1196/annals.1345.006 Mishra, 2013, Iron overload in Beta thalassaemia major and intermedia patients, Maedica (Buchar), 8, 328 Hershko, 2010, Pathogenesis and management of iron toxicity in thalassemia, Ann N Y Acad Sci, 1202, 1, 10.1111/j.1749-6632.2010.05544.x Henninger, 2012, Evaluation of MR imaging with T1 and T2* mapping for the determination of hepatic iron overload, Eur Radiol, 22, 2478, 10.1007/s00330-012-2506-2 Musallam, 2013, Iron overload in beta-thalassemia intermedia: an emerging concern, Curr Opin Hematol, 20, 187, 10.1097/MOH.0b013e32835f5a5c Melis, 2002, H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers, Haematologica, 87, 242 Longo, 1999, The influence of hemochromatosis mutations on iron overload of thalassemia major, Haematologica, 84, 799 Oudit, 2003, L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy, Nat Med, 9, 1187, 10.1038/nm920 Liuzzi, 2006, Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells, Proc Natl Acad Sci, 103, 13612, 10.1073/pnas.0606424103 Cabantchik, 2014, Labile iron in cells and body fluids: physiology, pathology, and pharmacology, Front Pharmacol, 5, 45, 10.3389/fphar.2014.00045 Murphy, 2010, Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment, J Card Fail, 16, 888, 10.1016/j.cardfail.2010.05.009 Bresgen, 2015, Oxidative stress and the homeodynamics of iron metabolism, Biomolecules, 5, 808, 10.3390/biom5020808 Jain, 2013, Mitochondrial reactive oxygen species regulate transforming growth factor-beta signaling, J Biol Chem, 288, 770, 10.1074/jbc.M112.431973 Telfer, 2009, Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone, Haematologica, 94, 1777, 10.3324/haematol.2009.009118 Lithanatudom, 2011, Enhanced activation of autophagy in beta-thalassemia/Hb E erythroblasts during erythropoiesis, Ann Hematol, 90, 747, 10.1007/s00277-010-1152-5 Sornjai, 2016, Dysregulation of ferroportin gene expression in beta(0)-thalassemia/Hb E disease, Ann Hematol, 95, 387, 10.1007/s00277-015-2572-z Tanno, 2010, Growth differentiation factor 15 in erythroid health and disease, Curr Opin Hematol, 17, 184 Adamsky, 2004, Decreased hepcidin mRNA expression in thalassemic mice, Br J Haematol, 124, 123, 10.1046/j.1365-2141.2003.04734.x Jones, 2015, Hepcidin is suppressed by erythropoiesis in hemoglobin E beta-thalassemia and beta-thalassemia trait, Blood, 125, 873, 10.1182/blood-2014-10-606491 Gardenghi, 2010, Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in beta-thalassemia, Hematol Oncol Clin North Am, 24, 1089, 10.1016/j.hoc.2010.08.003 Gardenghi, 2010, Hepcidin and Hfe in iron overload in beta-thalassemia, Ann N Y Acad Sci, 1202, 221, 10.1111/j.1749-6632.2010.05595.x Pasricha, 2013, Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: a longitudinal study, Blood, 122, 124, 10.1182/blood-2012-12-471441 Papanikolaou, 2005, Hepcidin in iron overload disorders, Blood, 105, 4103, 10.1182/blood-2004-12-4844 Kattamis, 2006, The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major, Haematologica, 91, 809 Guimaraes, 2015, Altered erythropoiesis and iron metabolism in carriers of thalassemia, Eur J Haematol, 94, 511, 10.1111/ejh.12464 Pak, 2006, Suppression of hepcidin during anemia requires erythropoietic activity, Blood, 108, 3730, 10.1182/blood-2006-06-028787 Weizer-Stern, 2006, Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera, Br J Haematol, 135, 129, 10.1111/j.1365-2141.2006.06258.x Folgueras, 2008, Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis, Blood, 112, 2539, 10.1182/blood-2008-04-149773 Kautz, 2015, Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia, Blood, 126, 2031, 10.1182/blood-2015-07-658419 Taher, 2013, Treating iron overload in patients with non-transfusion-dependent thalassemia, Am J Hematol, 88, 409, 10.1002/ajh.23405 Lucarelli, 2012, Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia, Cold Spring Harb Perspect Med, 2, 136, 10.1101/cshperspect.a011825 Musallam, 2013, Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia, Blood, 121, 2199, 10.1182/blood-2012-10-408021 Saliba, 2015, Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions, J Blood Med, 6, 197 Gardenghi, 2010, Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice, J Clin Invest, 120, 4466, 10.1172/JCI41717 Ramos, 2012, Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis, Blood, 120, 3829, 10.1182/blood-2012-07-440743 Corradini, 2010, BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice, Gastroenterology, 139, 1721, 10.1053/j.gastro.2010.07.044 Nai, 2011, TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals, Blood, 118, 4459, 10.1182/blood-2011-06-364034 Finberg, 2011, Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice, Blood, 117, 4590, 10.1182/blood-2010-10-315507 Casu, 2014, Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia, Haematologica, 124, e8, 10.3324/haematol.2015.133348 Schmidt, 2015, Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of beta-thalassemia intermedia, Am J Hematol, 90, 310, 10.1002/ajh.23934